Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M. J., Arcila, M. E., Arrieta, O., Planchard, D., de Marinis, F., Dingemans, A. M., Dziadziuszko, R., Faivre-Finn, C., Feldman, J., Felip, E., Curigliano, G., Herbst, R., Janne, P. A., John, T., Mitsudomi, T., Mok, T., Normanno, N., Paz-Ares, L., Ramalingam, S., Sequist, L., Vansteenkiste, J., Wistuba, I. I., Wolf, J., Wu, Y. L., Yang, S. R., Yang, J. C. H., Yatabe, Y., Pentheroudakis, G. and Peters, S. (2022). ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann. Oncol., 33 (5). S. 466 - 488. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Full text not available from this repository.

Abstract

The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the consensus was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where the available evidence is either limited or conflicting. The main topics identified for discussion were: (i) tissue and biomarkers analyses; (ii) early and locally advanced disease; (iii) metastatic disease and (iv) clinical trial design, patient's perspective and miscellaneous. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Passaro, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Leighl, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Blackhall, F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Popat, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kerr, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ahn, M. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Arcila, M. E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Arrieta, O.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Planchard, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Marinis, F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dingemans, A. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dziadziuszko, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Faivre-Finn, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Feldman, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Felip, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Curigliano, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Herbst, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Janne, P. A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
John, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mitsudomi, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mok, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Normanno, N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Paz-Ares, L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ramalingam, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sequist, L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vansteenkiste, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wistuba, I. I.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolf, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wu, Y. L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Yang, S. R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Yang, J. C. H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Yatabe, Y.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pentheroudakis, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Peters, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-698845
DOI: 10.1016/j.annonc.2022.02.003
Journal or Publication Title: Ann. Oncol.
Volume: 33
Number: 5
Page Range: S. 466 - 488
Date: 2022
Publisher: ELSEVIER
Place of Publication: AMSTERDAM
ISSN: 1569-8041
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; PHASE-III; 1ST-LINE TREATMENT; PD-L1 EXPRESSION; OPEN-LABEL; LEPTOMENINGEAL METASTASES; MOLECULAR CHARACTERISTICS; COMBINATION OSIMERTINIB; CHECKPOINT INHIBITORSMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69884

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item